Sasakawa Leprosy Initiative to Boost Support for Indonesia

January 25, 2025 02:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination, Makes Announcement on World Leprosy Day 2025

TOKYO, Jan. 25, 2025 /PRNewswire/ -- On the occasion of World Leprosy Day 2025 on January 26, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa announces that the Sasakawa Leprosy Initiative (SLI) will increase its support to Indonesia to combat the stigma and discrimination associated with leprosy and to promote early diagnosis and treatment of the disease.

Leprosy, also known as Hansen's disease, is an infectious disease caused by the bacterium Mycobacterium leprae that mainly affects the skin and peripheral nerves. For much of its long history, the cause was unknown, giving rise to many myths and misconceptions.

Since the introduction of WHO-recommended multidrug therapy (MDT) in 1981, some 18 million people worldwide have been cured of leprosy. However, around 200,000 new cases are reported each year, and many people affected by leprosy and their families continue to face rejection based on outdated stereotypes and superstitions.

After India and Brazil, Indonesia has the third highest number of cases of leprosy in the world. In 2023, it recorded 14,376 new cases, including 1,179 children. In addition, 826 people, including 21 children, had visible disabilities at the time of diagnosis, indicating that they were diagnosed late.

Yohei Sasakawa visiting a patient at Sumberglagah Hospital, Mojokerto Regency, East Java
Yohei Sasakawa visiting a patient at Sumberglagah Hospital, Mojokerto Regency, East Java

"Indonesia is one of the most important countries in the fight against leprosy," said Sasakawa. "Overcoming stigma and discrimination and promoting early diagnosis and treatment there will be key to accelerating the world's progress toward zero leprosy."

He said that from this year, SLI will intensify its support for Indonesia, working with government agencies, civil society organizations, research institutes, the media and others to raise awareness of leprosy and encourage people to seek treatment if they suspect they have the disease.

SLI already supports the Indonesian Ministry of Health's national leprosy program through the WHO, as well as providing assistance to NGOs and PerMaTa, an organization of persons affected by leprosy.

"Leprosy is a treatable disease. With appropriate and timely treatment, disabilities associated with leprosy can be prevented," said Al Kadri, PerMaTa's chairman. "But fear of prejudice and discrimination means that many people go undiagnosed and untreated."

Indonesia has a comprehensive strategy to tackle leprosy, according to Health Minister Budi Gunadi Sadikin, including public education campaigns, collaboration with tuberculosis initiatives to strengthen case detection and treatment, and support for social rehabilitation. "Through these measures, we aim to achieve a leprosy-free Indonesia, where everyone can live with dignity," he said.

As part of its support for Indonesia's efforts against the disease, SLI plans to identify several districts and work with local government agencies, healthcare providers and others to develop "zero leprosy" projects that can serve as models for the whole country.

About WHO Goodwill Ambassador Yohei Sasakawa

As chairman of The Nippon Foundation, Yohei Sasakawa focuses on finding solutions to humanitarian and other problems in many parts of the world, especially in Asia and Africa. For more than half a century, he has been working to eliminate leprosy, serving as WHO Goodwill Ambassador for Leprosy Elimination since 2001, and Japanese Government Goodwill Ambassador for the Human Rights of Persons Affected by Leprosy since 2007.

About Sasakawa Leprosy (Hansen's Disease) Initiative

Sasakawa Leprosy Initiative is a strategic alliance of WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa, the Sasakawa Health Foundation and The Nippon Foundation to realize a leprosy-free world. Since 1975, it has supported governments in their fight against leprosy through the WHO, contributing more than US$200 million. It has also made significant contributions to support organizations of persons affected by leprosy and has been instrumental in bringing leprosy to the attention of the United Nations, resulting in the adoption of several UN resolutions on the elimination of discrimination against persons affected by leprosy and their family members.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.